Berlin, Germany, 2 October 2018 ­- When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of dai...

Berlin, Germany, 2 October 2018 ­- According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved g...

26 September 2018 – A leading provider of assay solutions to pharma, biotech, and clinical research organisations has streamlined its approach to quality assurance an...

Bottom Line: Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) were significantly more likely to relapse than pediatric ALL patients, ...

Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of...

Mataró, Barcelona, Spain, September 26, 2018- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the co...

BERLIN, GERMANY, September 25, 2018 - Myelo Therapeutics GmbH announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to...